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Abstract
Summary Osteoporotic post-menopausal women patients in
two randomised trials comparing the anti-fracture efficacy
of strontium ranelate with placebo were separated into
tertiles according to their baseline levels of biochemical
markers of bone formation and resorption. The vertebral
anti-fracture efficacy of strontium ranelate was shown to be
independent of baseline bone turnover levels.
Introduction Bone turnover (BTO) levels vary among
women at risk of osteoporotic fracture. Strontium ranelate
is an anti-osteoporotic treatment increasing bone formation
and reducing bone resorption. It was hypothesised that its
anti-fracture efficacy would be independent of baseline
BTO levels.
Methods Post-menopausal women with osteoporosis from
two pooled studies were stratified in tertiles according to
baseline levels of two BTO markers: bone-specific alkaline
phosphatase(b-ALP,n=4995) and serum C-telopeptide cross-
links (sCTX, n=4891). Vertebral fracture risk was assessed
over 3 years with strontium ranelate 2 g/day or placebo.
Results In the placebo group, relative risk of vertebral
fractures increased with BTO tertiles by 32% and 24% for
patientsinthehighesttertileforb-ALPandCTX,respectively,
compared to those in the lowest tertile. In the strontium
ranelate group, incidences of vertebral fracture did not differ
significantly across BTO tertiles. Significant reductions in
vertebral fractures with strontium ranelate were seen in all
tertilesofbothmarkers,withrelativeriskreductionsof31%to
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e-mail: J.Collette@chu.ulg.ac.be47% relative to placebo. Risk reduction did not differ among
tertiles (b-ALP: p=0.513; sCTX: p=0.290).
Conclusion The vertebral anti-fracture efficacy of strontium
ranelate was independent of baseline BTO levels. Strontium
ranelate offers clinical benefits to women across a wide
range of metabolic states.
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Introduction
Osteoporosis is a complex disease, and many factors may
contribute to the skeletal fragility that underlies osteopo-
rotic fractures [1]. Two processes are thought to be
particularly important in post-menopausal osteoporosis.
First, during adult life, in both men and women, resorption
of bone tends to exceed bone formation at each of the basic
multicellular units that are responsible for bone remodel-
ling. Secondly, relative oestrogen deficiency in women after
the menopause increases the rate of bone remodelling,
accelerating the net loss of bone [2, 3]. During long-term
treatment, anti-resorptive anti-osteoporotic agents act pri-
marily by decreasing the rate of bone remodelling [4].
For example, during treatment with the bisphosphonate
alendronate, some biochemical markers of bone resorption
show a rapid decrease of 50% to 65% within 1 month of
treatment.However, thisisaccompanied byadelayed decrease
in markers of bone formation of approximately 50%, which
reaches a nadir between 6 and 12 months [5]. It might be
predicted thatbaseline bone turnover rates could influence the
effects of treatment with anti-resorptive and other anti-
osteoporoticagents.Forexample,anti-resorptiveagentsmight
be expected to be of greatest benefit to women with high
levelsofboneturnover,while boneformationagentsmight be
most effective in women with low rates of bone formation.
Studies of the effects of anti-resorptive agents on bone
mineral density (BMD) have generally shown larger treatment
effects in women with high pre-treatment levels of bone
turnover [6–10]. However, results for osteoporotic fracture
risk have been less consistent [11, 12]. The effects of
teriparatide, an agent that increases bone formation, on
BMD were also greater in women with high bone turnover
[13], but the reduction in the relative risk of osteoporotic
fracture was independent of the pre-treatment bone turnover
level [14].
Strontium ranelate is an oral anti-osteoporotic agent that
reduces the risk of vertebral [15], non-vertebral and hip [16]
fractures in post-menopausal osteoporotic women. Experi-
m e n t si nv i t r oa n di na n i m a l s[ 17, 18], as well as
measurements of biochemical markers of bone turnover in
osteoporotic women in a clinical trial [15], have shown that
strontium ranelate simultaneously stimulates bone forma-
tion and reduces bone resorption, although individual
effects are less pronounced than those induced by PTH or
bisphosphonates. Two previous analyses have demonstrated
that strontium ranelate reduces the risk to have a new
vertebral fracture in patients with a wide range of osteopo-
rosis severity: in osteopenic patients with and without
previous fractures, in osteoporotic patients without prevalent
vertebral fractures and in severe osteoporotic patients (at
least two prevalent vertebral fractures) [19, 20]. The purpose
of the present study was to determine whether the efficacy
of strontium ranelate in increasing lumbar BMD and
reducing vertebral fracture risk in post-menopausal women
is influenced by the pre-treatment level of biochemical
markers of bone turnover, using data obtained over 3 years
in two large placebo-controlled clinical trials, the Spinal
Osteoporosis Therapeutic Intervention (SOTI) study [15]
and the Treatment of Peripheral Osteoporosis (TROPOS)
study [16]. Given the specific effects on bone turnover and
its wide efficacy profile to date, we hypothesise that its
efficacy would be independent of pre-treatment bone
turnover levels.
Methods
The present analysis is based on pooled data on vertebral
fractures and markers of pre-treatment bone turnover taken
from two randomised, double-blind, placebo-controlled,
international studies in post-menopausal women with
osteoporosis, that demonstrated the anti-fracture efficacy
of strontium ranelate 2 g/day. The SOTI study [15] was
aimed at vertebral anti-fracture efficacy, and the TROPOS
study [16] was aimed at peripheral (non-vertebral) frac-
tures. However, vertebral fractures were evaluated in
TROPOS as a pre-specified secondary endpoint in those
women who had a spinal radiograph at baseline and at least
one post-baseline.
Patients
Patients for both the SOTI and TROPOS studies were
included initially in a common, open-label run-in study, the
FIRST study [21]. Detailed inclusion criteria have been
published previously [15, 16, 21]. In brief, for inclusion in
FIRST, women had to be Caucasian, post-menopausal for at
least 5 years, ambulatory and considered to be osteoporotic
and at high risk of fracture. During FIRST, the calcium and
vitamin D status of all women was assessed, and they were
given daily supplements of up to 1,000 mg of elemental
calcium and up to 800 IU of vitamin D for a period of
2 weeks to 6 months. Supplementation doses and duration
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calcium and 25-OH vitamin D status. After the run-in period,
eligible women were proposed for enrolment in either the
SOTI or TROPOS studies, and supplementation was contin-
ued at the same doses throughout the randomised treatment
periods of both these studies. The SOTI study included
women≥50yearsofagewithlowlumbarBMD (<0.840g/cm
2
measured with Hologic instruments, T-score ≤−2.4) and at
least one prevalent vertebral fracture confirmed by spinal
radiography. The TROPOS study included women with
femoral neck BMD <0.600 g/cm
2 and aged ≥74 years or
70–74 years with one additional risk factor (history of
osteoporotic fracture after menopause, residence in a retire-
ment home, frequent falls or maternal history of osteoporotic
fracture of the hip, spine or wrist).
Study design and efficacy measurements
Patients were randomisedto receivestrontium ranelate 2 g/day
or placebo for 5 years (TROPOS) or 4 years followed by a
1-year treatment-switch period (SOTI). In both studies, main
efficacy analyses were performed at 3 years, and the vertebral
fracture data over 3 years were used for the present analysis.
Baseline refers to the commencement of the SOTI and
TROPOS studies, not the time of inclusion in FIRST.
Vertebral fractures were determined from radiographs
taken at baseline and annually thereafter and were analysed
in the same way in both studies. Radiographs were analysed
by the semi-quantitative method of Genant et al. [22, 23],
using a four-point grading scale: grade 0—normal; grade 1—
mild deformity (20–25% decrease in at least one vertebral
height); grade 2—moderate deformity (25–40% decrease);
and grade 3—severe deformity (>40% decrease). A new
vertebral fracture was defined as a change from a non-
fractured vertebra (grade 0) to a vertebra rated grade 1 or
higher. All radiographs were analysed at a central facility
(CEMO, France) blinded to treatment assignment but not to
temporal sequence.
Lumbar L2–4 and femoral neck BMD were measured at
baseline, and lumbar BMD was measured every 6 months
post-baseline by dual-energy X-ray absorptiometry using
Hologic devices. All scans were analysed centrally, and a
programme of cross-calibration across centres was per-
formed throughout both studies [24].
Blood samples were collected at baseline, 3 months,
6 months, and then every 6 months. Serum samples were
stored at −80°C and analysed centrally after a maximum
6 months period of storage (University of Liège, Belgium).
Serumconcentrationofbone-specificalkalinephosphatase(b-
ALP), a marker of bone formation, was measured by
immunoradiometric assay (Tandem® Ostase® Beckman
Coulter, San Diego, CA, USA). Serum concentration of
C-telopeptide cross-links (sCTX), a marker of bone
resorption, was measured using an enzyme- linked
immunosorbent assay (Serum CrossLaps®ELISA–Nordic
Bioscience Diagnostic, formerly Osteometer BioTech,
Herlev, Denmark).
All the assays were performed in duplicate per batch of
maximum140and86unknownserumsamplesforb-ALPand
sCTX, respectively. If the CVon the duplicate measurement
was higher than 15%, the sample was re-assayed in a run
control. In each assay run, two quality control samples (QCs)
were assayed before and after the unknown samples. The
assay run was validated if the CV on the duplicate
measurement of a QC was lower or equal to 15%, if the
QCs results were in their respective 2SD ranges determined
previously and if the difference between the results obtained
before and after the unknown samples did not exceed 15%.
Both clinical studies were conducted in accordance with
the ethical principles stated in the Declaration of Helsinki,
1964, as revised inHong Kong,1989. The study protocolwas
approved by independent ethics committees in each country
and/or centre. All patients gave written informed consent.
Statistical analysis
All analyses were performed in accordance with the
intention-to-treat principle: The population included all
patients having a baseline and post-baseline lumbar X-ray
and having a baseline value for b-ALP or sCTX.
Groups were compared at baseline on the lumbar and
femoral BMD and corresponding T-scores using an
ANOVA analysis, adjusted or not on age.
Vertebral fracture risk was assessed as the number of
patients with at least one new osteoporotic vertebral
fracture, analysed by the Kaplan–Meier method. Patients
were stratified into tertiles of baseline (pre-treatment) levels
of b-ALP and sCTX. The boundaries of the tertiles and the
normal ranges for b-ALP and sCTX are given in Table 1.
Between-treatment differences in vertebral fracture risk
over 3 years for each tertile were assessed using an
unadjusted Cox model. Sensitivity analysis was performed
using a Cox model adjusted for baseline lumbar BMD.
Table 1 Tertile boundaries and normal ranges for markers of bone
turnover (b-ALP and sCTX)
Tertile 1 Tertile 2 Tertile 3
b-ALP (µg/L)
a ≤10.0 >10.0–≤13.3 >13.3
sCTX (ng/mL)
b ≤0.423 >0.423–≤0.626 >0.626
ab-ALP, bone-specific alkaline phosphatase: normal range, 2.9–14.5 µg/L
(premenopausal women); 3.8–22.6 µg/L (post-menopausal women)
bsCTX, serum C-telopeptide cross-links: normal range, 0.112–
0.323 ng/mL (pre-menopausal women); 0.153–0.625 ng/mL (post-
menopausal women)
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model, were performed for those patients who were in the
lowest tertile for both b-ALP and sCTX (representing
patients with the lowest bone turnover) and for patients in
the highest tertile for both b-ALP and sCTX (representing
those with the highest bone turnover).
Results
Patients
Of the 6,740 patients randomised in the two studies (1,649 in
SOTI, 5,091 in TROPOS), 5,082 had a lumbar spinal
radiograph at baseline and one or more post-baseline
radiograph. Of these patients, 4,955 had a baseline measure-
ment of b-ALP, and 4,891 patients had a baseline measure-
ment of sCTX. These patients were then stratified into tertiles
of b-ALP (n=1,683 in tertile 1, n=1,642 in tertile 2 and
1,630 in tertile 3) or sCTX (n=1,631 in tertile 1, n=1,630 in
tertile 2 and n=1,630 in tertile 3). Baseline characteristics of
patients, stratified into tertiles of baseline b-ALP and sCTX,
are shown in Tables 2 and 3. The mean age of patients was
approximately 74 years. Most variables were similar across
tertiles. However, there were significant progressive reduc-
tions in lumbar and femoral neck BMD (ANOVA, p<0.001
for both sites), most obvious in the T-scores, with increasing
tertiles of b-ALP and sCTX. There were no other relevant
differences in baseline characteristics between tertiles,
including in the levels of 25OH vitamin D, creatinine or
PTH. Regarding treatment group differences, baseline
characteristics were similar in the strontium ranelate and
placebo groups regardless of the tertile considered (as an
example, lumbar BMD values are described in Table 3).
Tertile 1 Tertile 2 Tertile 3
According to b-ALP level n=1,683 n=1,642 n=1,630
Age (years) 74.5±6.2 73.7±6.3 73.8±6.0
Lumbar BMD (g/cm
2) 0.792±0.146 0.781±0.148 0.760±0.149
Lumbar BMD T-score −2.9±1.5 −3.0±1.5 −3.2±1.6
Mean number of prevalent vertebral fractures 2.5±2.2 2.5±2.2 2.6±2.3
Femoral neck BMD (g/cm
2) 0.573±0.072 0.569±0.073 0.560±0.073
Femoral neck T-score −2.9±0.7 −3.0±0.7 −3.1±0.7
Mean number of previous peripheral fractures 1.6±0.9 1.6±0.9 1.6±0.9
According to sCTX level n=1,631 n=1,630 n=1,630
Age (years) 73.6±6.2 73.9±6.3 74.4±6.0
Lumbar BMD (g/cm
2) 0.798±0.149 0.778±0.150 0.755±0.145
Lumbar BMD T-score −2.8±1.5 −3.0±1.6 −3.3±1.5
Mean number of prevalent vertebral fractures 2.6±2.3 2.5±2.2 2.5±2.2
Femoral neck BMD (g/cm
2) 0.579±0.075 0.567±0.070 0.556±0.072
Femoral neck T-score −2.9±0.7 −3.0±0.6 −3.1±0.6
Mean number of previous peripheral fractures 1.6±0.9 1.6±0.9 1.6±1.0
Table 2 Patients’ characteristics
at baseline by tertiles of b-ALP
and sCTX
Expressed as mean ± standard
deviation
b-ALP bone-specific alkaline
phosphatase, BMD bone mineral
density, sCTX serum
C-telopeptide cross-links
Table 3 Lumbar BMD values at baseline by tertiles of b-ALP and sCTX and treatment
Strontium ranelate Placebo
Tertile 1 Tertile 2 Tertile 3 Tertile 1 Tertile 2 Tertile 3
b-ALP
Lumbar BMD (g/cm²) 0.793±0.140 0.781±0.153 0.759±0.152 0.790±0.153 0.781±0.143 0.760±0.146
T-score −2.8±1.5 −2.9±1.6 −3.2±1.6 −2.9±1.6 −3.0±1.5 −3.2±1.5
sCTX
Lumbar BMD (g/cm²) 0.797±0.145 0.780±0.153 0.755±0.148 0.800±0.153 0.776±0.146 0.755±0.142
T-score −2.8±0.5 −3.0±1.6 −3.3±1.5 −2.8±1.6 −3.0±1.5 −3.3±1.5
Expressed as mean ± standard deviation
b-ALP bone-specific alkaline phosphatase, BMD bone mineral density, sCTX serum C-telopeptide cross-links
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The incidence of new vertebral fractures among patients
treated with placebo was higher in patients in the highest
tertile than in patients in the lowest tertile (26.5% vs
21.1% in b-ALP tertiles 3 and 1, p=0.010, and 26.3% vs
21.2% in sCTX tertiles 3 and 1, p=0.043, respectively).
Compared with the low turnover group (tertile 1), the
relative risk to have a new vertebral fracture in patients
with a high bone turnover level was increased over 3 years
by 32% when considering b-ALP (RR=1.32, 95% CI
[1.06; 1.62]) and 24% when considering sCTX (RR=1.24,
95% CI [1.00; 1.54]). This result was confirmed when
comparing the incidence of new vertebral fracture in
placebo patients in the subset with the lowest tertile for
both b-ALP and sCTX with placebo patients in the highest
tertile for both b-ALP and sCTX (RR=1.47, 95% CI
[1.08; 1.97], p=0.012).
Strontium ranelate was associated with a reduction in the
relative risk of vertebral fracture, relative to placebo, of
40% (RR=0.60, 95% CI [0.53–0.70], p<0.001). When
patients were stratified by tertiles of baseline levels of bone
turnover markers, significant RR reductions with strontium
ranelate were seen in each tertile of b-ALP (31%, 42% and
42% for tertiles 1, 2 and 3, respectively). The same results
were observed for tertiles of sCTX, with RR reductions of
37%, 32% and 47% for tertiles 1 to 3, respectively (Table 4,
Fig. 1). The magnitudes of the treatment effects were not
significantly different between tertiles (interaction test p=
0.513 for b-ALP tertiles, p=0.290 for sCTX tertiles).
Results were similar after adjustment on lumbar BMD.
Tertile 1 Tertile 2 Tertile 3
SR Placebo SR Placebo SR Placebo
By b-ALP level
Events
a 114 155 107 175 115 203
Incidence (%) 14.9 21.1 14.3 23.7 16.4 26.5
Relative risk [95% CI] 0.69 [0.54; 0.88] 0.58 [0.46; 0.74] 0.58 [0.46; 0.73]
p value 0.003 <0.001 <0.001
Relative risk reduction (%) 31 42 42
Absolute risk reduction (%) 6.2 9.4 10.2
NNT 17 11 10
By sCTX level
Events
a 105 153 122 181 103 195
Incidence (%) 13.8 21.2 16.9 24.1 14.7 26.3
Relative risk [95% CI] 0.63 [0.49; 0.81] 0.68 [0.54; 0.85] 0.53 [0.42; 0.67]
p value <0.001 <0.001 <0.001
Relative risk reduction (%) 37 32 47
Absolute risk reduction (%) 7.4 7.2 11.6
NNT 14 14 9
Table 4 Incidence of vertebral
fracture over 3 years of treat-
ment with strontium ranelate
(SR) compared with placebo,
according to tertiles of pre-
treatment b-ALP and sCTX
level
CI confidence interval, NNT
number needed to treat
aTotal number of patients hav-
ing at least one new vertebral
fracture during the 3-year period
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Fig. 1 Incidence of vertebral fractures over 3 years according to
tertiles of b-ALP (upper panel) and sCTX (lower panel). SR strontium
ranelate, PL placebo
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b o t hb - A L Pa n ds C T X( n=881), strontium ranelate
treatment produced a RR reduction of 33% compared to
placebo (RR=0.67, 95% CI [0.47; 0.95], p=0.023;Fig.2).
Among patients in the highest tertile for both b-ALP and
sCTX (n=867), the relative risk reduction with strontium
ranelate was 49% (RR=0.51, 95% CI [0.37; 0.70],
p <0.001). The fracture incidences in the strontium
ranelate group were comparable, and the magnitude of
the treatment effect was not significantly different between
patients in the lowest and highest tertiles for both markers
(interaction test p=0.254).
Given the increasing incidence of fractures with increas-
ing bone turnover in patients treated with placebo, the
absolute reduction in fracture risk with strontium ranelate
was larger for higher tertiles of bone turnover markers. The
number needed to treat (NNT) for 3 years to prevent one
first new vertebral fracture ranged from 17 and 14 for the
lowest tertiles of b-ALP and sCTX, respectively, to 10 and
9 for the highest tertiles (Table 4).
Bone mineral density
Lumbar BMD increased progressively during the 3-year
analysis period in patients treated with strontium ranelate,
but remained virtually unchanged in placebo-treated patients
(Fig. 3). The increase in lumbar BMD with strontium
ranelate, relative to baseline, at 3 years was 12.5%, 14.6%
and 16.5% in b-ALP tertile 1, 2 and 3, respectively, and 12.6%,
13.9% and 16.9% in sCTX tertile 1, 2, and 3, respectively
(p<0.001 in all tertiles; Fig. 3). At each yearly time point,
significant between-group differences in favour of strontium
ranelate were observed in all tertiles (p<0.001 vs placebo at
all time points for all tertiles of both b-ALP and sCTX).
Discussion
The main result from this analysis is that 3 years of
treatment with strontium ranelate produced similar reduc-
tions in the risk of vertebral fracture, relative to placebo, in
women with post-menopausal osteoporosis, irrespective of
their baseline bone turnover level, consistent with our stated
hypothesis. Substantial and significant reductions in frac-
ture risk were seen across all tertiles of pre-treatment
b-ALP (a marker of bone formation) and all tertiles of sCTX
(a marker of bone resorption), and the size of the treatment
effect did not differ significantly between tertiles of either
biochemical marker. When women who were in the lowest
tertile for both b-ALP and sCTX were compared with those in
the highest tertile for both markers, significant relative risk
reductions wereseenin bothgroups, witha similar magnitude
between the two groups. We further reported that in the
placebo group, a high level of bone turnover at baseline is
associated with a higher risk to have a new vertebral fracture
in accordance to previous studies [25].
Bone turnover markers increase in women after the
menopause. In one study, b-ALP, assayed using the same
method as in the present study, was significantly higher
in post-menopausal (13.7 μg/L) than pre-menopausal
women (10.8 μg/L, p<0.0001) [26]. Other studies have
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SR strontium ranelate, PL placebo
-2
0
2
4
6
8
10
12
14
16
18
-2
0
2
4
6
8
10
12
14
16
18
Baseline M12 M24 M36
Baseline M12 M24 M36
C
h
a
n
g
e
 
i
n
 
l
u
m
b
a
r
 
B
M
D
 
(
%
)
 
C
h
a
n
g
e
 
i
n
 
l
u
m
b
a
r
 
B
M
D
 
(
%
)
 
T3 SR
T2 SR
T1 SR
T1 PL
T2 PL
T3 PL
T3 SR
T2 SR
T1 SR
T1 PL
T2 PL
T3 PL
Fig. 3 Changes in lumbar bone mineral density (BMD) at 12, 24 and
36 months by tertiles of b-ALP (upper panel) and sCTX (lower panel)
and treatment group. SR strontium ranelate, PL placebo
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of8.2μg/L[27] and 8.8 μg/L [28]. Reported mean values for
post-menopausal women with osteoporosis range from
approximately 12.5 μg/L [13] to 16.7 μg/L [27]a n d
18.1 μg/L [29]. The boundaries of the middle tertile for
b-ALP in our sample were >10.0 and ≤13.3 μg/L and were
slightly lower than the corresponding boundaries for osteo-
porotic subjects in the fracture intervention trial (FIT, 11.7
and 14.9 μg/L) [12]. Regarding sCTX, levels in healthy pre-
menopausal women have been measured at 1,748 pmol/L
(corresponding to 0.225 ng/mL) comparedwith 2,952 pmol/L
(corresponding to 0.380 ng/mL) in post-menopausal women
[30]. Similarly, Garnero et al. [5] obtained levels of 0.299
and 0.556 ng/mL in pre- and post-menopausal women. The
boundaries of the middle tertile for sCTX in our sample of
post-menopausal osteoporotic women was >0.423 to
≤0.626 ng/mL (or 3,283 to ≤4,861 pmol/L), slightly higher
than in the FITstudy (2,337 to 3,665 pmol/L) [12]. Thus, the
baseline levels of bone turnover markers in the present
analysis are consistent with those in previous studies in post-
menopausal women.
At baseline, higher tertiles of b-ALP and sCTX were
associated with lower BMD, both at the lumbar spine and the
femoral neck. Previous studies have reported that high bone
turnover is correlated with low BMD [25, 31] and predicts
higher rates of future bone loss in post-menopausal women
[32, 33]. High bone turnover has also been associated with
increased fracture risk, even after adjustment for BMD [31,
34, 35]. In our analysis, rates of prevalent vertebral and
peripheral osteoporotic fractures at baseline did not differ
between tertiles of bone turnover markers. However, the
incidence of vertebral fractures during the study in the placebo
group increased across ascending tertiles of both bone markers
by 24% or more depending on the marker considered, with
significant differences when comparing the lowest and highest
tertiles (b-ALP or CTX independently or both b-ALP and CTX),
suggesting that high bone turnover is a risk factor for fracture.
Strontium ranelate produced substantial increases in
lumbar BMD independently of the baseline level of
b-ALP or sCTX. Larger effects of treatment on BMD in
women with higher baseline bone turnover level have been
reported for many anti-osteoporotic drugs, including anti-
resorptive agents such as calcitonin [6], hormone replace-
ment therapy [7] and bisphosphonates [8–10] and the bone
formation agent, teriparatide [13]. Strontium ranelate
treatment increased lumbar BMD in post-menopausal
women across the range of baseline bone turnover and
produced significant increases in BMD, relative to placebo,
at each yearly time point in the present analysis.
The influence of baseline bone turnover level on the
efficacy of anti-osteoporotic drugs on fracture risk has been
less widely studied than BMD, and the results have been
less consistent. In an analysis of a subgroup of 1,593 patients
from three randomised trials of risedronate [11], vertebral anti-
fracture efficacy was compared in women with baseline bone
turnover levels, assessed by urinary excretion of deoxypyr-
idinoline, above and below the normative median. At 3 years,
the relative risk of vertebral fracture in patients with high
bone turnover was 0.52, similar to that in patients with low
bone turnover (0.54). A recent analysis in 6,459 osteoporotic
and non-osteoporotic women in the FIT study [12] concluded
that the efficacy of alendronate in reducing non-vertebral
fractures was greater in those with higher baseline bone
turnover levels, although there was some inconsistency
between different biochemical markers. The vertebral anti-
fractureefficacyofalendronatewasalsoinfluencedbybaseline
bone turnover in non-osteoporotic women, but no significant
influence was found among osteoporotic women [12].
In the case of the bone formation agent, teriparatide, the
relative risk reduction for osteoporotic fractures (vertebral and
non-vertebral combined) was found to be similar for women in
all tertiles of baseline bone turnover markers [14]. However, in
that analysis, the risk of fracture increased markedly across
tertiles of bone turnover markers, in both the placebo and
teriparatide-treated groups. For example, the risks of fracture in
the teriparatide group were 0.03, 0.04 and 0.08 in the low,
middle and high tertiles of b-ALP, respectively. Thus, the
absolute risk reduction with teriparatide was influenced by
baseline bone turnover, and the number needed to treat to
prevent one fracture decreased with higher tertiles of bone
turnover markers. In the present study, the risk of fracture in the
strontium ranelate group was similar across tertiles of baseline
b-ALP and sCTX, whereas the fracture risk in women treated
with placebo increased. The absolute reduction in fracture risk
achieved with strontium ranelate treatment was therefore
greater in women with higher pre-treatment bone turnover.
In a range of in vitro and in vivo experimental models,
strontium ranelate has been shown to simultaneously reduce
bone resorption and increase bone formation [18, 36, 37],
without any change in bone mineralization [38–40]. Thus,
strontium ranelate rebalances bone turnover in favour of
bone formation. This effect of strontium ranelate on bone
turnover may contribute to its anti-fracture efficacy in
women with widely differing bone turnover status.
It is increasingly recognised that osteoporosis is a
multifactorial disease. BMD is widely used both in
diagnosis and fracture risk prediction. However, BMD
accounts for only a modest proportion of fracture risk, and
the majority of osteoporotic fractures occur in women who
do not meet the World Health Organization definition of
osteoporosis based on BMD (T-score −2.5 or less). Other
clinical risk factors also contribute substantially to fracture
risk [41, 42]. The recently introduced FRAX fracture risk
assessment tool provides a framework for estimating fracture
risk in individuals from clinical risk factors, including age, body
mass index, previous fracture, parental history of fracture and
Osteoporos Int (2010) 21:233–241 239current smoking, with or without the use of BMD [43]. A
previous study demonstrated that the efficacy of a 3-year
treatment with strontium ranelate on the risk of vertebral
fractures is independent of baseline BMD and all of the above
clinical risk factors [19]. The present analysis indicates that
elevated levels of bone turnover markers is another risk factor
for vertebral fracture and shows that the 3-year efficacy of
strontium ranelate is also independent of the baseline bone
turnover level. Three-year treatment with strontium ranelate
therefore reduces vertebral fracture risk in post-menopausal
women with a wide spectrum of risk factors for these fractures.
The main limitation of this study is that the results were
based on post hoc analyses using pooled data from two studies
with different entry criteria. However, both studies included
women from a common run-in study (the FIRST study), and
vertebral fracture, BMD and bone turnover data were collected
using the same methodology. There were no significant
differences in patients’ characteristics at baseline between the
strontiumranelateandplacebogroups,andtheonlydifferences
among patients in the tertiles of bone turnover markers are
r e l a t e dt ol u m b a ra n df e m o r a ln e c kB M D .P o o l i n go fd a t aw a s
therefore unlikely to haveaffected the conclusions of the study.
On the other hand, pooling of data allowed an adequate
sample size and number of fractures to compare treatments
after stratification of patients into tertiles and ensured that
women with a wide range of disease severity and bone
turnover were included in the analysis.
In conclusion, strontium ranelate showed significant
vertebral anti-fracture efficacy in post-menopausal osteopo-
rotic women in each tertile of markers of pre-treatment bone
formation andresorption. The relative reductions in vertebral
fracture risk achieved by strontium ranelate were indepen-
dent of baseline bone turnover level. These results indicate
that strontium ranelate offers clinical benefits to women
across a wide range of metabolic states and disease severity.
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